| Name | Title | Contact Details |
|---|
The VentriFlo True Pulse Pump is a novel, truly pulsatile blood pumping system designed to achieve superior outcomes, reduce costs and improve safety for pediatric & adult patients who require cardiopulmonary support during surgery or in the ICU.
DermaSensor is a Miami-based health technology company designing tools to better equip primary care providers for skin cancer checks.
Gamma Medica-Ideas (GM-I), Inc is a Northridge, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
At Clarify, we are improving the lives of patients and those who care for them by building the brains of the digital healthcare system of the future. We partner with forward-looking providers and payers to optimize episode workflows, improve patient experience, increase volume, and maximize bonuses. We deliver innovative digital and analytics solutions that enable patients to obtain, and our customers to deliver, more satisfying, better outcome, higher value healthcare.
BioSig Technologies, Inc. (NASDAQ: BSGM) is a medical device company that is developing a proprietary biomedical signal processing technology platform to address an unmet technology need in the rapidly growing $4.6+ billion electrophysiology (EP) marketplace. Led by a proven management team, world-class Board of Directors and Scientific Advisory Board, Los Angeles-based BioSig Technologies is preparing to commercialize its PURE EP™ System. The PURE EP™System is a surface electrocardiogram (ECG) and intracardiac multichannel recording and analysis system designed to assist electrophysiologists in making crucial clinical decisions in real-time by acquiring and displaying high-fidelity cardiac signal recordings even at undetectable levels (until now) with high accuracy to help identify appropriate catheter ablation targets - areas of tissue to destroy that create a heart rhythm disturbance (arrhythmia). BioSig aims to deliver technology to improve upon catheter ablation treatments for the prevalent and potentially deadly arrhythmias, Atrial Fibrillation and Ventricular Tachycardia. PURE EP™ System is an innovative platform, offering potential benefits over current technologies including increased accuracy, reduced noise and interference, clinical information previously not available and potential elimination of the need for repeat procedures. BioSig has partnered with Minnetronix on technology development and has received FDA 510(k) clearance for the PURE EP™ System in August 2018. BioSig Technologies, Inc. is a Nasdaq company: NASDAQ:BSGM.